SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

Inflammatory Bowel Disease

SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

Lancet Gastroenterol Hepatol

Alexander JL, Moran GW, Gaya DR, Raine T, Hart A, Kennedy NA, Lindsay JO, MacDonald J, Segal JP, Sebastian S, Selinger CP, Parkes M, Smith PJ, Dhar A, Subramanian S, Arasaradnam R, Lamb CA, Ahmad T, Lees CW, Dobson L, Wakeman R, Iqbal TH, Arnott I, Powell N, Inflammatory Bowel Disease section of the British Society of Gastroenterology and the the Inflammatory Bowel Disease Clinical Research Group.

doi: 10.1016/S2468-1253(21)00024-8

Inflammatory Bowel Disease

T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease

J Crohns Colitis

Reuken PA, Andreas N, Grunert PC, Glöckner S, Kamradt T, Stallmach A

doi: 10.1093/ecco-jcc/jjab147

Further Publications

Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs Cohort of Inflammatory Bowel Disease Patients with Diverse Exposure to Immunosuppressive Medications

Gastroenterology

Khan N, Mahmud N

doi: 10.1053/j.gastro.2021.05.044

Inflammatory Bowel Disease

Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease

Inflamm Bowel Dis

Dailey J, Kozhaya L, Dogan M, Hopkins D, Lapin B, Herbst K, Brimacombe M, Grandonico K, Karabacak F, Schreiber J, Liang BT, Salazar JC, Unutmaz D, Hyams JS

doi: 10.1093/ibd/izab207

Inflammatory Bowel Disease

Adverse Events Following SARS-CoV-2 mRNA Vaccination: Among Patients with Inflammatory Bowel Disease

Am J Gastroenterol

Botwin GJ, Li D, Figueiredo J, Cheng S, Braun J, McGovern DPB, Melmed GY

doi: 10.14309/ajg.0000000000001342

Inflammatory Bowel Disease

Keeping on the high quality of healthcare in Greek Inflammatory Bowel Disease patients in the SARS-CoV-2 era

No abstract available

Inflammatory Bowel Disease

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

United European Gastroenterol J.

Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A

doi: 10.1177/2050640620929133.

Further Publications

Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease

Lancet Gastroenterol Hepatol

Alexander JL, Selinger CP, Powell N, British Society of Gastroenterology Inflammatory Bowel Disease section and the Inflammatory Bowel Disease Clinical Research Group.

doi: 10.1016/S2468-1253(21)00374-5

Inflammatory Bowel Disease

Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory Bowel Disease

Dig Dis Sci.

Pratt PK Jr, Nunes D, Long MT, Farraye FA

doi: 10.1007/s10620-

Related content

SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease

Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs Cohort of Inflammatory Bowel Disease Patients with Diverse Exposure to Immunosuppressive Medications

Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease

Adverse Events Following SARS-CoV-2 mRNA Vaccination: Among Patients with Inflammatory Bowel Disease

Keeping on the high quality of healthcare in Greek Inflammatory Bowel Disease patients in the SARS-CoV-2 era

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease

Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory Bowel Disease